Trubion

Trubion is a biotechnology company that was founded in 2002 and is based in Seattle, Washington. The company specializes in the development of monoclonal antibody-based drugs for the treatment of autoimmune diseases and cancer.

History

Trubion was founded by a group of scientists who had previously worked at Immunex, a biotechnology company that was acquired by Amgen in 2002. The founders of Trubion wanted to continue their work on monoclonal antibodies, which are proteins that can bind to specific targets in the body and can be used to treat a variety of diseases.

Products

Trubion's main product is a monoclonal antibody called TRU-015, which is being developed for the treatment of rheumatoid arthritis. TRU-015 works by binding to a protein called CD20, which is found on the surface of certain immune cells. By binding to CD20, TRU-015 can help to reduce the activity of these immune cells, which can help to reduce the symptoms of rheumatoid arthritis.

In addition to TRU-015, Trubion is also developing a number of other monoclonal antibodies for the treatment of autoimmune diseases and cancer.

Acquisition by Emergent BioSolutions

In 2010, Trubion was acquired by Emergent BioSolutions, a biopharmaceutical company based in Rockville, Maryland. As part of the acquisition, Emergent BioSolutions gained access to Trubion's monoclonal antibody technology and its pipeline of drug candidates.

See also

• Monoclonal antibodies
• Autoimmune diseases
• Cancer
• Biotechnology